在患有极低低密度脂蛋白水平的患者中使用静止剂与改善生存率有关
Nicholas J Leeper1, Reza Ardehali, Emil M deGoma
1Department of Medicine, Stanford University School of Medicine, VA Palo Alto HealthCare System, Palo Alto, Calif, USA. nleeper@cvmed.stanford.edu
Circulation
|August 1, 2007
概括
用他类药物进行激进的脂质管理是冠状动脉心脏病的标准. 这项研究发现,对于患有非常低低密度脂蛋白 (LDL) 胆固醇的患者,他类药物治疗是安全有效的,改善了生存率.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 积极的脂质管理是冠状动脉心脏病患者目前的标准.
- 在患有极低低密度脂蛋白 (LDL) 胆固醇水平 (<60 mg/dL) 的患者中,他类药物治疗的安全性和有效性需要进一步研究.
研究的目的:
- 评估在LDL胆固醇水平低于60mg/dL的患者中使用他类药物治疗的安全性和临床结果.
主要方法:
- 从第三级护理中心对6107名LDL水平<60毫克/分升的患者进行了回顾性分析.
- 达丁类药物治疗被定义为在低LDL测量后150天内处方.
- 倾向性得分匹配被用来调整接受他类药物治疗的可能性.
主要成果:
- 对于60%的确诊患者 (n=2564) 进行了类固醇药物治疗.
- 在倾向性得分调整后,他类药物治疗与改善的生存率有关 (HR,0.65;95% CI,0.53至0.80).
- 静止剂的使用并没有增加恶性瘤,转氨酶升高或狂犬病的风险.
结论:
- 对于患有非常低的LDL胆固醇水平的患者,他类药物治疗似乎是安全的.
- 在这群人群中,他类药物治疗与改善生存结果有关.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


